OBJECTIVE: The diagnostic criteria of chronic fatigue syndrome (CFS) define a heterogeneous population composed of several subgroups. Past efforts to identify subgroup markers have met with mixed success. This study was designed to examine natural killer cell activity (NKCA) as a potential subgroup marker by comparing the clinical presentations of CFS patients with and without clinically reduced NKCA. METHODS: Forty-one female CFS patients were classified into having either low or normal NKCA levels. These subgroups were then compared on objective measures of cognitive functioning and subjective assessments of fatigue, vigor, cognitive impairment, and daytime dysfunction. RESULTS: Relative to CFS patients in the normal-NKCA subgroup, low-NKCA patients reported less vigor, more daytime dysfunction, and more cognitive impairment. In addition, low-NKCA patients performed less on objective measures of cognitive functioning relative to normal-NKCA patients. CONCLUSIONS: The results are offered as preliminary evidence in support of using NKCA as an immunological subgroup marker in CFS. Findings are also discussed in terms of known associations between dysregulated immune functions, somatic symptoms, and psychological stress.
OBJECTIVE: The diagnostic criteria of chronic fatigue syndrome (CFS) define a heterogeneous population composed of several subgroups. Past efforts to identify subgroup markers have met with mixed success. This study was designed to examine natural killer cell activity (NKCA) as a potential subgroup marker by comparing the clinical presentations of CFS patients with and without clinically reduced NKCA. METHODS: Forty-one female CFS patients were classified into having either low or normal NKCA levels. These subgroups were then compared on objective measures of cognitive functioning and subjective assessments of fatigue, vigor, cognitive impairment, and daytime dysfunction. RESULTS: Relative to CFS patients in the normal-NKCA subgroup, low-NKCA patients reported less vigor, more daytime dysfunction, and more cognitive impairment. In addition, low-NKCA patients performed less on objective measures of cognitive functioning relative to normal-NKCA patients. CONCLUSIONS: The results are offered as preliminary evidence in support of using NKCA as an immunological subgroup marker in CFS. Findings are also discussed in terms of known associations between dysregulated immune functions, somatic symptoms, and psychological stress.
Authors: Kristine A Donovan; Paul B Jacobsen; Brent J Small; Pamela N Munster; Michael A Andrykowski Journal: J Pain Symptom Manage Date: 2008-05-20 Impact factor: 3.612
Authors: Gordon Broderick; Jim Fuite; Andrea Kreitz; Suzanne D Vernon; Nancy Klimas; Mary Ann Fletcher Journal: Brain Behav Immun Date: 2010-05-04 Impact factor: 7.217
Authors: Kristine A Donovan; Kevin D Stein; Morgan Lee; Corinne R Leach; Onaedo Ilozumba; Paul B Jacobsen Journal: Support Care Cancer Date: 2014-08-22 Impact factor: 3.603
Authors: Andrea T White; Alan R Light; Ronald W Hughen; Lucinda Bateman; Thomas B Martins; Harry R Hill; Kathleen C Light Journal: Psychophysiology Date: 2010-03-04 Impact factor: 4.016
Authors: Mary A Fletcher; Xiao R Zeng; Kevin Maher; Silvina Levis; Barry Hurwitz; Michael Antoni; Gordon Broderick; Nancy G Klimas Journal: PLoS One Date: 2010-05-25 Impact factor: 3.240